tetano
Editor, Senior Moderator
Expert Opin Drug Discov
. 2022 Jan 24;1-16.
doi: 10.1080/17460441.2022.2029843. Online ahead of print.
The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19
Christiana Mantzourani[SUP] 1 2 [/SUP], Sofia Vasilakaki[SUP] 1 2 [/SUP], Velisaria-Eleni Gerogianni[SUP] 1 2 [/SUP], George Kokotos[SUP] 1 2 [/SUP]
Affiliations
Abstract
Introduction: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused the devastating pandemic named coronavirus disease 2019 (COVID-19). Unfortunately, the discovery of antiviral agents to combat COVID-19 is still an unmet need. Transmembrane serine protease 2 (TMPRSS2) is an important mediator in viral infection and thus, TMPRRS2 inhibitors may be attractive agents for COVID-19 treatment.
Areas covered: This review article discusses the role of TMPRSS2 in SARS-CoV-2 cell entry and summarizes the inhibitors of TMPRSS2 and their potential anti-SARS activity. Two known TMPRSS2 inhibitors, namely camostat and nafamostat, approved drugs for the treatment of pancreatitis, are under clinical trials as potential drugs against COVID-19.
Expert opinion: Due to the lack of the crystal structure of TMPRSS2, homology models have been developed to study the interactions of known inhibitors, including repurposed drugs, with the enzyme. However, novel TMPRSS2 inhibitors have been identified through high-throughput screening, and appropriate assays studying their in vitro activity have been set up. The discovery of TMPRSS2's crystal structure will facilitate the rational design of novel inhibitors and in vivo studies and clinical trials will give a clear answer if TMPRSS2 inhibitors could be a new weapon against COVID-19.
Keywords: COVID-19; Clinical trials; SARS-CoV-2; inhibitors; transmembrane serine protease 2 (TMPRSS2).
. 2022 Jan 24;1-16.
doi: 10.1080/17460441.2022.2029843. Online ahead of print.
The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19
Christiana Mantzourani[SUP] 1 2 [/SUP], Sofia Vasilakaki[SUP] 1 2 [/SUP], Velisaria-Eleni Gerogianni[SUP] 1 2 [/SUP], George Kokotos[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35072549
- DOI: 10.1080/17460441.2022.2029843
Abstract
Introduction: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused the devastating pandemic named coronavirus disease 2019 (COVID-19). Unfortunately, the discovery of antiviral agents to combat COVID-19 is still an unmet need. Transmembrane serine protease 2 (TMPRSS2) is an important mediator in viral infection and thus, TMPRRS2 inhibitors may be attractive agents for COVID-19 treatment.
Areas covered: This review article discusses the role of TMPRSS2 in SARS-CoV-2 cell entry and summarizes the inhibitors of TMPRSS2 and their potential anti-SARS activity. Two known TMPRSS2 inhibitors, namely camostat and nafamostat, approved drugs for the treatment of pancreatitis, are under clinical trials as potential drugs against COVID-19.
Expert opinion: Due to the lack of the crystal structure of TMPRSS2, homology models have been developed to study the interactions of known inhibitors, including repurposed drugs, with the enzyme. However, novel TMPRSS2 inhibitors have been identified through high-throughput screening, and appropriate assays studying their in vitro activity have been set up. The discovery of TMPRSS2's crystal structure will facilitate the rational design of novel inhibitors and in vivo studies and clinical trials will give a clear answer if TMPRSS2 inhibitors could be a new weapon against COVID-19.
Keywords: COVID-19; Clinical trials; SARS-CoV-2; inhibitors; transmembrane serine protease 2 (TMPRSS2).